Patients undergoing radical surgery.
Conditions
Interventions
Intervention 1: Rivastigmine (manufactured by Galenus Pharmaceutical Company) will be given to the patient three times a day in doses of 1.5 mg (4.5 mg per day) in the form of infusion before, during
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 60 Years
Inclusion criteria
Inclusion criteria: All patients underwent radical surgery Age over 60 years
Exclusion criteria
Exclusion criteria: History of psychiatric disorders Patients in need of emergency surgery Patients with a Mini-Mental State Examination Score (MMSE) of less than 15 Current treatment with cholinesterase inhibitors Using psychiatric drugs Using haloperidol Contraindication for the use of rivastigmine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bleeding rate. Timepoint: before and after intervention. Method of measurement: The amount of bleeding during the operation.;Postoperative delirium. Timepoint: before and after intervention. Method of measurement: Patient delirium one hour after surgery and at the time of discharge from the intensive care unit.;Duration of stay in the ICU. Timepoint: before and after intervention. Method of measurement: Number of days the patient stays in the intensive care unit after surgery.;Length of hospital stay. Timepoint: before and after intervention. Method of measurement: Number of days the patient stays in the hospital after surgery.;Duration of postoperative consciousness. Timepoint: before and after intervention. Method of measurement: The number of hours the patient regains consciousness after surgery.;Postoperative nausea and vomiting. Timepoint: before and after intervention. Method of measurement: The number of times a patient vomits after surgery until discharge from the intensive care unit.;Postoperative dizziness. Timepoint: before and after intervention. Method of measurement: Duration of postoperative sensory disturbances and confusion.;Train-of-four Fade evaluation. Timepoint: before and after intervention. Method of measurement: Evaluation of peripheral nerve excitability to evaluate neuromuscular block.;Extubation time. Timepoint: before and after intervention. Method of measurement: Duration of extubation of the patient after administration of neuromuscular blocking agent.;The amount of opiate used. Timepoint: before and after intervention. Method of measurement: The amount of opiate used after surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Electrolyte disturbance. Timepoint: before and after intervention. Method of measurement: Having an electrolyte disorder such as hyponatremia.;Hemoglobin. Timepoint: before and after intervention. Method of measurement: Serum hemoglobin concentration. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactkia kazemzadeh hanani
Shahid Beheshti University of Medical Sciences
Outcome results
None listed